AnaptysBio (NASDAQ:ANAB) had its price objective increased by equities researchers at Jefferies Group from $6.59 to $145.00 in a report issued on Monday, February 19th, The Fly reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Jefferies Group’s target price would suggest a potential upside of 24.82% from the stock’s previous close. Jefferies Group also issued estimates for AnaptysBio’s FY2021 earnings at ($5.67) EPS and FY2022 earnings at ($0.80) EPS.
Several other research firms have also commented on ANAB. SunTrust Banks lifted their price target on AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. ValuEngine upgraded AnaptysBio from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Credit Suisse Group set a $135.00 price target on AnaptysBio and gave the company an “outperform” rating in a report on Tuesday, January 23rd. Robert W. Baird reissued a “buy” rating and issued a $144.00 price objective (up previously from $81.00) on shares of AnaptysBio in a research note on Friday, January 19th. Finally, Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $129.67.
AnaptysBio (NASDAQ ANAB) traded up $2.75 during mid-day trading on Monday, reaching $116.17. The company had a trading volume of 354,461 shares, compared to its average volume of 293,516. The company has a current ratio of 17.93, a quick ratio of 17.93 and a debt-to-equity ratio of 0.02. AnaptysBio has a one year low of $18.15 and a one year high of $134.00. The company has a market cap of $2,697.66, a price-to-earnings ratio of -71.27 and a beta of 1.94.
Several large investors have recently bought and sold shares of ANAB. Evercore Wealth Management LLC purchased a new position in shares of AnaptysBio during the 3rd quarter worth approximately $100,000. Legal & General Group Plc boosted its position in AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 1,951 shares during the period. New York State Common Retirement Fund purchased a new position in AnaptysBio in the 2nd quarter valued at approximately $168,000. Nationwide Fund Advisors boosted its position in AnaptysBio by 89.5% in the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,776 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in AnaptysBio in the 4th quarter valued at approximately $212,000. 99.25% of the stock is owned by hedge funds and other institutional investors.
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.